

REFERENCES

References

- 1- Appleyard M: Acute coronary syndrome. *Circulation, Journal of the American Heart Association*, web site 2008.
- 2- John L, Antman E, Thomas H, et al: Acute coronary syndromes: The Journal of the American Medical Association. JAMA 298:828, 2007.
- 3- Malmperg K, Yusuf S, Gerstein HC, et al: Impact of diabetes on long term prognosis in patients with unstable angina and non-Q wave myocardial infarction: Results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. *Circulation* 102:1014, 2000.
- 4- Ravkilde J, Horder M, Gerhardt W, et al: Diagnostic performance and prognostic value of serum troponin-T in suspected myocardial infarction. *Scand, J Clin Lab Invest* 53:677, 1993.
- 5- Westerhout CM, Fu Y, Lauer MS, et al: Short and long-term stratification in acute coronary syndrome: The added value of quantitative ST-segment depression and multiple biomarkers. *Am J Coll Cardiol* 48:939-947, 2006.
- 6- Newby LK, Roe MT, Chen AY, et al: Frequency and clinical implications of discordant creatin kinase-MB and troponin measurements in acute coronary syndrome. *Am J Coll Cardiol* 47:312-318, 2006.
- 7- Alpert JS, Thygesen K, Antman E, Bassand JP: Myocardial infarction redefined a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. *Am J Coll Cardiol* 36:959-969, 2000.

- 8- Christopher P, Thomas H: Approach to the patient with chest pain, *Braunwald's Heart Disease. A Textbook of Cardiovascular Medicine*: Peter Libby (eds.), Eighth edition, Vol.3, CH 49, p1195, 2008.
- 9- Jensen G, Nyboe J, Appleyard M, et al: Risk factors for acute myocardial infarction in Copenhagen, II: Smoking, alcohol intake, physical activity, obesity, oral contraception, diabetes, lipids, and blood pressure. *Eur Heart J* 12(3): 298-300, 1991.
- 10- Wilson PW, D'Agostino RB, Levy D, et al: Prediction of coronary heart disease using risk factor categories. *Circulation* 97(18): 1837-1847, 1998.
- 11- Statistical Fact Sheet Populations: Older Americans and Cardiovascular Disease: American Heart Association; 2004
- 12- Lloyd-Jones DM, Larson MG, Beiser A et al: Lifetime risk of developing coronary heart disease. *Lancet*, 353:89-92, 2003.
- 13- Kannel WB, Levine BS: Coronary heart disease risk in people 65 years of age and older. *Prog Cardiovasc Nurs* 18:135-140, 2003
- 14- Online Mendelian Inheritance in Man, OMIM. McKusick-Nathans Institute for Genetic Medicine, Johns Hopkins University (Baltimore, MD) and National Center for Biotechnology Information, National Library of Medicine. Available at: <http://www.ncbi.nlm.nih.gov/omim/>. Accessed March 6, 2003.
- 15- Williams RR, Hunt SC, Heiss G, et al: Usefulness of cardiovascular family history data for population-based preventive medicine and medical research (the Health Family Tree Study and the NHLBI Family Heart Study). *Am J Cardiol.*; 87:129-135, 2001.
- 16- Sullivan JL: Are menstruating women protected from heart disease because of, or in spite of, estrogen? Relevance to the iron hypothesis. *Am Heart J* 145:190, 2003.

- 17- Mikkola TS, Clarkson TB: Estrogen replacement therapy, atherosclerosis, and vascular function. *Cardiovasc Res* 53:605, 2002.
- 18- Mendelsohn ME: Genomic and nongenomic effects of estrogen in the vasculature. *Am J Cardiol* 90:3F, 2002.
- 19- Zanger D, Yang BK, Ardans J, et al: Divergent effects of hormone therapy on serum markers of inflammation in postmenopausal women with coronary artery disease on appropriate medical management. *J Am Coll Cardiol* 36:1797, 2000.
- 20- Yamada Y, Izawa H, Ichihara S, et al: Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. *N Engl J Med* 347:1916, 2002.
- 21- Burke AP, Farb A, Malcom GT, et al: Effect of risk factors on the mechanism of acute thrombosis and sudden coronary death in women. *Circulation* 97:2110, 1998.
- 22- English JL, Jacobs LO, Green G, et al: Effect of the menstrual cycle on endothelium-dependent vasodilation of the brachial artery in normal young women. *Am J Cardiol* 82:256, 1998.
- 23- Sader MA, McCredie RJ, Griffiths KA, et al: Oestradiol improves arterial endothelial function in healthy men receiving testosterone. *Clin Endocrinol (Oxf)* 54:175, 2001.
- 24- Weksler B: Hemostasis and thrombosis. In Douglas PS (ed): *Cardiovascular Health and Disease in Women*. 2nd ed. Philadelphia, WB Saunders, pp 157–177, 2002.
- 25- Arbustini E, Dal Bello B, Morbini P, et al: Plaque erosion is a major substrate for coronary thrombosis in acute myocardial infarction. *Heart* 82:269, 1999.
- 26- Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of

High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation* 106:3143-3421, 2002.

27- Heart Disease and Stroke Statistics - 2005 Update: American Heart Association and the American Stroke Association; 2005.

28- Sarrel PM: The differential effects of oestrogens and progestins on vascular tone. *Hum Reprod Update* 5:205-209, 2001.

29- Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report: National Heart, Lung, and Blood Institute in cooperation with the National Institute of Diabetes and Digestive and Kidney Diseases U.S. Department of Health and Human Services 98:4083, 1998.

30- Wilson PW, D'Agostino RB, Sullivan L, et al: Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. *Arch Intern Med* 162:1867-1872, 2002.

31- Alpert MA: Obesity cardiomyopathy; Pathophysiology and evolution of clinical syndrome. *Am J Med Sci*.321:225-236, 2001.

32- Greenfield JR, Samaras K, Jenkins AB, et al: Obesity Is an Important Determinant of Baseline Serum C-reactive protein Concentration in Monozygotic Twins, Independent of Genetic Influences. *Circulation* 109:3022-3028, 2004.

33- Rissanen P, Franssila-Kallunki A, Rissanen A: Cardiac Parasympathetic Activity Is Increased by Weight Loss in Healthy Obese Women. *Obes Res* 9:637-643, 2001.

34- Ambrose JA, Barua RS: The pathophysiology of cigarette smoking and cardiovascular disease: An update. *Am J Coll Cardiol* 43:1731-1737, 2004.

35- Mayhan WG, Sharpe GM: Effect of cigarette smoke extract on arteriolar dilatation in vivo. *J Appl Physiol* 81:1996-2003.

- 36-Bermudez EA, Rifai N, Buring J, et al.: Interrelationships Among Circulating Interleukin-6, C-Reactive Protein, and Traditional Cardiovascular Risk Factors. *Arterioscler Thromb Vasc Biol* 22:1668-1673, 2002.
- 37- Kannel WB, Wolf PA, Castelli WP, et al.: Fibrinogen and risk of cardiovascular disease. The Framingham Study. *JAMA* 258:1183-1186, 1997.
- 38- Smith CJ, Fischer TH: Particulate and vapor phase constituents of cigarette mainstream smoke and risk of myocardial infarction. *Atherosclerosis*.158:257-267, 2001.
- 39- Craig WY, Palomaki GE, Haddow JE: Cigarette smoking and serum lipid and lipoprotein concentrations: an analysis of published data. *BMJ* 298:784-788, 1989.
- 40- Gale EAM and Anderson JV: Diabetes mellitus and other disorders of metabolism, A Textbook of clinical medicine KUMAR and CLARK (eds.), sixth edition, CH 19, p 1101, 2005.
- 41- World Health Organization. Annex Table 2: Deaths by cause, sex and mortality stratum in WHO regions, estimates for 2002. The world health report, 2004.
- 42-Marfella R, D'Amico M, Esposito K, et al: The ubiquitin-proteasome system and inflammatory activity in diabetic atherosclerotic plaques. *Diabetes care* 55:622, 2006.
- 43- Chobanian AV, Bakris GL, Black HR, et al: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. *JAMA* 289: 2560 -2571, 2003.
- 44- Thom T, Haase N, Rosamond W, et al. Heart Disease and Stroke Statistics-2006 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. *Circulation* 113:e85-151, 2006.

- 45-Whelton PK, He J, Appel LJ, et al. Primary prevention of hypertension: clinical and public health advisory from The National High Blood Pressure Education Program. *JAMA* 288:1882-1888, 2002.
- 46- Eric J.Topol, Hintinder S.Gurm, JoAnne Micale Foody: Dyslipidemia, "*Topol and Marso, Manual of Cardiovascular Medicine*": Chapter 42, Second edition, P 526, 2004.
- 47- Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults: Executive summery of the third report of national Cholesterol Education Program (NCEP) (Adult treatment III). *JAMA* 285:2486, 2001.
- 48- Wagner AM, Perez A, Zapico E, et al: Non-HDL Cholesterol and Apolipoprotein B in the Dyslipidemic Classification of Type 2 Diabetic Patients. *Diabetes Care* 26:2048-2051, 2003.
- 49- Ridker PM, Rifai N, Braunwald E, et al: Long-Term Effects of Pravastatin on Plasma Concentration of C-reactive Protein. *Circulation* 100:230-235, 1999.
- 50- Abate N, Vega GL, Grundy SM: Variability in cholesterol content and physical properties of lipoproteins containing apolipoprotein B-100. *Atherosclerosis* 104:159-171, 1993.
- 51- Vega GL, Grundy SM: Does measurement of apolipoprotein B have a place in cholesterol management? *Arteriosclerosis* 10:668-671, 1990.
- 52- Bogaty P, Brophy JM, Boyer L, et al: Fluctuating Inflammatory Markers in Patients With Stable Ischemic Heart Disease. *Arch Intern Med*,165:221-226, 2005.
- 53- Sano T, Tanaka A, Namba M, et al: C-Reactive Protein and Lesion Morphology in Patients With Acute Myocardial Infarction. *Circulation* 108:282-285, 2003.
- 54- Stensvold I, Tverdal A, Urdal P, et. al: Non-fasting serum triglyceride concentration and mortality from coronary heart disease and

any cause in middle aged Norwegian women. *BMJ* 307:1318-1322, 2003.

55- Sjöholm A, Nystrom T: Endothelial inflammation in insulin resistance. *Lancet* 365:610, 2005.

56- Grundy SM, Cleeman II, Brewer HB Jr, et al: Definition of metabolic syndrome: Report of the National Heart, Lung and Blood Institute/ American Heart Association conference on scientific issues related to definition. *Circulation* 109:433, 2004.

57- Ridker PM, Buring JE, Cook NR, et al: C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: 8-year follow up of 14719 initially healthy American women. *Circulation* 107: 391, 2003.

58- Burke AP, Tracy RP, Kolodgie F, et al: Elevated C - reactive protein Values and Atherosclerosis in Sudden Coronary Death: Association With Different Pathologies. *Circulation.*;105:2019 – 2023, 2002.

59- Arroyo-Espliguero R, Avanzas P, Cosin-Sales J, et al: C-reactive protein elevation and disease activity in patients with coronary artery disease. *Eur Heart J.*; 25:401 – 408, 2004.

60-Elguindy MS, Farrag AA: Coronary artery disease; Essentials of cardiovascular medicine, third edition, CH 15, 401:403, 2007.

61- Avanzas P, Arroyo-Espliguero R, Cosin-Sales J, et al: Markers of inflammation and multiple complex stenoses (pancoronary plaque vulnerability) in patients with non-ST segment elevation acute coronary syndromes. *Heart.*; 90:847 – 852, 2004.

62-DeWood MA, Stifter WF, Simpson CS, et al: Coronary arteriographic findings soon after non-Q-wave myocardial infarction. *N Engl J Med* 315:417-423, 1986.

63- Ohtani T, Ueda Y, Mizote I, et al: Number of yellow plaques detected in a coronary artery associated with future risk of acute coronary syndrome. Detection of vulnerable patients by angioscopy. *Am J Coll Cardiol* 47:2194, 2006.

- 64- Shah PK: Mechanisms of Plaque Vulnerability and Rupture. Am J Coll Cardiol 41:Supplement, 2003.
- 65- Arbustini E, Dal Bello B, Morbini P, et al.: Plaque erosion is a major substrate for coronary thrombosis in acute myocardial infarction. Heart 82:269-272, 1999.
- 66- National Heart, Lung and Blood Institute. Heart Attack Warning Signs. Retrieved November 22, 2006.
- 67- Avanzas P: Acute Coronary Syndrome. American Heart Association. Retrieved November 25, 2006.
- 68- McSweeney JC, Cody M, O'Sullivan P, et. al: "Women's early warning symptoms of acute myocardial infarction". Circulation 108 (21): 2619-23, 2003.
- 69- Lee D, Kulick D, Marks J.: Heart Attack (Myocardial Infarction) by MedicineNet.com. Retrieved November 28, 2006.
- 70- Podick DH.: "Decreased recognition of the post-myocardial infarction (Dressler) syndrome in the postinfarct setting: does it masquerade as "idiopathic pericarditis" following silent infarcts?" Chest 126 (5): 1410-1, 2004.
- 71- Davis TM, Fortun P, Mulder J, et.al : "Silent myocardial infarction and its prognosis in a community-based cohort of Type 2 diabetic patients: the Fremantle Diabetes Study". *Diabetologia* 47 (3): 395-9, 2004.
- 72- Rubin's Pathology - Clinicopathological Foundations of Medicine. Maryland: Lippincott Williams & Wilkins, p. 549, 2001.
- 73- Myocardial infarction: diagnosis and investigations, GPnotebook, retrieved November 27, 2006.
- 74- DE Fenton: Myocardial infarction heart scan - Patient information from University College London. Retrieved November 27, 2006.

- 75- Alpert JS: Definition of myocardial infarction- a global consensus document of The Joint ESC/ACC/AHA/WHF/WHO Task Force for the Redefinition of myocardial infarction, 2007 (in press).
- 76- Garas S: Myocardial Infarction. eMedicine. Retrieved November 22, 2006.
- 77- Kasper DL, Braunwald E, Harrison's Principles of Internal Medicine. New York: McGraw-Hill, p. 1444, 2005.
- 78- Zimetbaum PJ, Josephson ME: Use of electrocardiogram in acute myocardial infarction. N Engl J Med 348:933, 2003.
- 79- Bayes-de-Luna A, Wagner G, Birnbaum Y, et al: A new terminology for the left ventricular walls and location of myocardial infarcts that present Q-wave based on the standard of cardiac magnetic resonant imaging. Circulation 114:1755, 2006.
- 80- Pope JH, Ruthazer R, Bateman TM, et al: The impact of electrocardiographic left ventricular hypertrophy and bundle branch block in the triage and outcome of ED patients with a suspected acute coronary syndrome: A multicenter study. Am J Emerg Med 22:156, 2004.
- 81-Deepak P., Michael A.: Acute myocardial infarction, :"*Topol and Marso, Manual of Cardiovascular Medicine*": Chapter 1, Second edition, P 5, 2004.
- 82- Eisenman A: Troponin assays for the diagnosis of myocardial infarction and acute coronary syndrome: where do we stand? Expert Rev Cardiovasc Ther 4:509-14, 2006.
- 83- Elliott M, Eugene Braunwald: ST-elevation myocardial infarction: Pathology, Pathophysiology and Clinical features. *Braunwald's Heart Disease. A Textbook Of Cardiovascular Medicine*: Peter Libby (eds.), Eighth edition, Vol.3, CH 50, p1229, 2008.
- 84- Cheitlin MD, Armstrong WF, Aurigemma GP, et al: ACC/AHA/ASE 2003 Guideline update of clinical application of echocardiography: A report of the American College of Cardiol-

gy/American Heart Association Task Force on Practice Guidelines. American College of Cardiology website, 2006.

85- Antman EM, Hand M, Armstrong PW, et al: July 2007 Focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: A report of American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Am J Coll Cardiol, 2007.

86- Klocke FJ, Baird MG, Bateman TM, et al: ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging. A report of American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACS/AHA/ASNC Committee to revise the 1995 guidelines for the clinical use of radionuclide imaging). American College of Cardiology website, 2006.

87- Pohost JM, Hung L, Doyle M: Clinical use of cardiovascular magnetic resonance. Circulation 108:647, 2003.

88- Brown AL, Mann NC, Daya M, et al: Demographic, belief, and situational factors influencing the decision to utilize emergency medical services among chest pain patients. Rapid Early Action for Coronary Treatment (REACT) study. Circulation 102:173-178, 2000.

89- Heart attack first aid. MedlinePlus. Retrieved December 3, 2006.

90- Act in Time to Heart Attack Signs - NHLBI. Retrieved December 13, 2006.

91- "Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group." Lancet 343:311-22, 1994.

92- Verheugt FW, Gersh BJ, Armstrong PW: "Aborted myocardial infarction: a new target for reperfusion therapy." *Eur Heart J* 27(8): 901-4, 2006.

93- Rossi S, editor. *Australian Medicines Handbook* 2006. Adelaide: Australian Medicines Handbook; 2006.

94- "Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia." *Circulation* 89 (4):1545-56, 1994.

95- Morrow DA, Antman EM, Braunwald E et al: Clopidogrel As Adjunctive Reperfusion Therapy (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28 Investigators. "Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 Trial.". *Circulation* 112 (25):3846-54, 2005.

96- Sutton AG, Graham R, Campbell PG, et al: Randomized trial of rescue angioplasty versus a conservative approach for the field fibrinolysis in ST-segment elevation myocardial infarction: The Middlesbrough Early Revascularization to Limit Infarction (MERLIN). *Am J Coll Cardiol* 44:287, 2004.

97- Boersma E; The Primary Coronary Angioplasty vs. Thrombolysis Group. "Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients." *Eur Heart J* 27(7):779-88, 2006.

98- Bradley EH, Herrin J, Wang Y, et al: Strategies for reducing the door-to-balloon time in acute myocardial infarction. *N Engl J Med* 355(22): 2308-20, 2006.

99- Aversano T, Avresano LT, Passamani E, et al: Thrombolytic therapy vs primary percutaneous coronary intervention for myocardi-

al infarction in patients presenting to hospitals without on-site cardiac surgery: a randomized controlled trial". JAMA 287 (15): 1943-51,2002.

100- Mehta RH, Harjai KJ, Cox DA, et al: Comparison of coronary stenting versus conventional balloon angioplasty on five year mortality in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Am J Coll Cardiol 96:901, 2005.

101- Tcheng JE, Kandzari DE, CADILLAC Investigators: "Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial." Circulation 108 (11): 1316-23, 2003.

102- Raja SG, Haider Z, Ahmad M, et. al: "Saphenous vein grafts: to use or not to use?" Heart Lung Circ; 13(4): 403-409, 2004.

103- Colwell JA, Nesto RW: The platelet in diabetes: Focus on prevention of ischemic events. Diabetic care 26:2181, 2003.

104- Zeller N, Steg PG, Ravisy J, et al: Prevalence and impact of metabolic syndrome on hospital outcome in acute myocardial infarction. Arch Int. Med. 165:1192, 2005.

105- Maheta SS, Silver RJ, Goldfine AB, et. al: Comparison of aspirin resistance in type 1 versus type 2 diabetes mellitus. Am J Cardiol 97:567, 2006.

106- Fateh-Moghadam S, Cabeze N, Plockinger U, et. al: prevalence of aspirin resistance in patients with type 2 diabetes. Acta Diabetol 42:99, 2005.

107- Richard W.Nesto: Diabetes and heart disease, *Braunwald's Heart Disease. A Textbook Of Cardiovascular Medicine*: Peter Libby (eds.), Eighth edition, Vol.3, CH 60, p1550-1558, 2008.

- 108-Yusuf S, Zhao F, Mehta SR, et al: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndrome without ST-segment elevation. *N Engl J Med* 345:494, 2001.
- 109- Lincoff AM: Important triad in cardiovascular medicine: diabetes, coronary intervention, and platelet glycoprotein IIb/IIIa receptor blockade. *Circulation* 107:1556, 2003.
- 110- Kereiakes DJ, Lincoff AM, Anderson KM, et al: abciximab survival advantages following percutaneous coronary intervention is predicted by clinical risk profile. *Am J Cardiol* 90:628, 2002.
- 111- Topol Ej, Mark DB, Lincoff AM, et al: Outcomes at one-year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: Results from multicenter randomized trial. EPISTENT investigators. Evaluation of platelet glycoprotein IIb/IIIa inhibitors for stenting. *Lancet* 354:2019, 1999.
- 112- Labinaz N, Madan M, O'Shea JO, et al : Comparison of one-year outcomes following coronary stenting in diabetic versus non diabetic patients (from the Enhanced Suppression of the Platelet glycoprotein IIb/IIIa Receptor with Integrilin Therapy [ESPRIT] trial). *Am J Cardiol* 90:585, 2002.
- 113- Heitzer T, Koke K, Ollmann I, et al: Platelet glycoprotein IIb/IIIa receptor blockade improves vascular nitric oxide bioavailability in patients with coronary artery disease. *Circulation* 108:536, 2003.
- 114- Gurm HS, Sarembock IJ, Kereiakes DJ, et al: Use of bivalirudin during percutaneous coronary intervention in patients with diabetes mellitus: An analysis from the Randomized Evaluation in Percutaneous Coronary Intervention Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial: *Am J Cardiol* 45:1932, 2005.
- 115- Cooper-Dehoff R, Cohen JD, Bakris GL, et al: Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medication (findings from the Interna-

tional VErapamil SR-Trandolapril study [INVEST]). Am J Cardiol 98:890, 2006.

116- McDonald CG, Majumdar SR, Mahon JL, et. al: The effectiveness of beta blockers after myocardial infarction in patients with type 2 diabetes. Diabetes Care 28:2113, 2005.

117- Kopecky SL: Effects of beta blocker, particularly carvedilol, on reducing the risk of events after acute myocardial infarction. Am J Cardiol 98:1115, 2006.

118- Brogan GX, Peterson ED, Bhatt DL, et al: Treatment disparities in the care of patients with and without diabetes presented with non ST-segment elevation acute coronary syndrome. Diabetes care 29:9, 2006.

119- Nesto RW, Zarich S: Acute myocardial infarction in diabetes mellitus: Lessons learned from ACE inhibition. Circulation 97:12, 1998.

120- Zuanetti G, Latinr R, Magioni AP, et al: Effects of ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction. Circulation 96:4239, 1997.

121- Gustafsson I, Torp-Pederson C, Kober L, et. al: Effect of angiotensin-converting enzyme inhibitor trandolapril on mortality and morbidity in diabetic patients with left ventricular dysfunction after acute myocardial infarction. Trace Study Group, Am J Cardiol 34:83, 1999.

122- Pfeffer MA, McMurry JJV, Velazquez EJ, et. al: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349:1893, 2003.

123- McFarlane SI, Kumar A, Sowers JR, et al: Mechanisms by which ACE inhibitors prevent diabetes and cardiovascular disease. Am J Cardiol 91:30, 2003.

- 124- Heart Outcome Prevention Evaluation (HOPE) study investigators: Effect of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus. Results of the HOPE study and MICRO-HOPE substudy. *Lancet* 355:253, 2000.
- 125- Ray KK, Cannon CP. "The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes." *Am J Coll Cardiol* 46(8):1425-1433, 2005.
- 126- Keating G, Plosker G: "Eplerenone: A review of its use in left ventricular systolic dysfunction and heart failure after acute myocardial infarction.". *Drugs* 64 (23): 2689-2707, 2004.
- 127- Flaherty JD, Davidson CJ, Malemberg K, et al: Diabetes and coronary re-vascularization. *JAMA* 293:1501, 2005.
- 128- Thomas H: ACC/AHA Guidelines for unstable angina and non ST-elevation myocardial infarction, Braunwald's Heart Disease. A Textbook Of Cardiovascular Medicine: Peter Libby (eds.), Eighth edition, Vol.3, CH 53, p1351, 2008.
- 129- Kehat I, Kenyagin-Karsenti, Snir M, et.al: Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes. *J Clin Invest* 108:407-414, 2001
- 130- Dai W, Kloner RA: Myocardial regeneration by embryonic stem cell transplantation: present and future trends. *Expert Rev Cardiovasc Ther* 4:375-383, 2006.
- 131- Toma C, Cahill KS, Pittenger MF, et. al.: Human mesenchymal stem cells differentiate to cardiomyocyte phenotype in the adult murine heart. *Circulation* 105:93-98, 2002.

- 132- Glavis BG, Brunelli S, Sampaolesi M, et. al: Complete repair of dystrophic skeletal muscle by mesoangioblasts with enhanced migration ability. *J Cell Biol* 174:231, 2006.
- 133- Galli D, Innocenzi A, Satszewsky L, et.al : Mesoangioblasts, vessel-associated multipotent stem cells, repair the infarct heart by multiple cellular mechanisms: A comparison with bone marrow progenitor cells. *Arterioscler Thromb Vasc Biol* 25:692-697, 2005.
- 134- Oh H, Gallardo TD, Cannon CP et. al: Cardiac progenitor cells from adult myocardium: Homing, differentiation and fusion after infarction. *Proc Natl Acad Sci U S A* 100 (21): 12313 -12318, 2003.
- 135- Stefanie D, Douglas L, Bradfute SB, et. al: Emerging therapies and strategies in the treatment of heart failure, *Braunwald's Heart Disease. A Textbook Of Cardiovascular Medicine*: Peter Libby (eds.), Eighth edition, Vol.3, CH 29, p701, 2008.
- 136- Strauer BE, Zeus T, Brehm M, et. al: Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow transplantation in humans. *Circulation* 106:1913-1918, 2002.
- 137- Assmus B, Schachinger V, Teupe C, et. al: Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). *Circulation* 106:3009-3017, 2002.
- 138- Wollert KC, Meyer GP, Lotz J, et. al: Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. *Lancet* 364:141-148, 2004.
- 139- Fernandez-Aviles F, San Roman JA, Garcia-Frade J, et. al: Experimental and clinical regenerative capability of human bone marrow cells after myocardial infarction. *Circ Res* 95:742-748, 2004.
- 140- Janssens S, Dubois C, Boegert J, et. al: Autologous bone marrow-derived stem-cell transfer after ST-elevation myocardial infarction.

tion: double-blind, randomized controlled trial. *Lancet* 367:113-121, 2006.

141- Lunde K, Solheim S, Aakhus S, et. al: Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. *N Engl J Med* 355:1199-1209, 2006.

142- Schachinger V, Erbs S, Elsasser A, et. al: Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. *N Engl J Med* 355:1210-1221, 2006.

143- Rossi S, editor: *Australian Medicines Handbook* 2006. Adelaide: Australian Medicines Handbook; 2006.

144- Elliott M, Eugene Braunwald : ST-elevation myocardial infarction: Pathology, Pathophysiology and clinical features, *Braunwald's Heart Disease. A Textbook Of Cardiovascular Medicine*: Peter Libby (eds.), Eighth edition, Vol.3, CH 50, p1224, 2008.

145- P.K. Nigam : Biochemical markers of myocardial injury. *Indian Journal of Clinical Biochemistry* 22:10-17, 2007.

146- Giannitsis E, Katus HA: Biomarkers of necrosis for risk assessment and management of ST-elevation myocardial infarction, cardiovascular biomarkers: pathophysiology and disease management. In Morrow DA (ed.): Totowa, NJ, Humana Press, pp119-128, 2006.

147- Apple FS, Quist HE, Parvin CA, et al: Plasma 99 percentile reference limits for cardiac troponin and creatin kinase-MB mass for use with European Society of Cardiology/American College of Cardiology consensus recommendations. *Clin Chem* 49:1331, 2003.

148- Apple FS: Tissue specificity of cardiac troponin I, cardiac troponin T and creatin kinase-MB. *Clin Chem Acta* 284:151, 1999.

149- Elliott M, Eugene Braunwald: ST-elevation myocardial infarction: Pathology, Pathophysiology and clinical features, *Braunwald's*

Heart Disease. A Textbook Of Cardiovascular Medicine: Peter Libby (eds.), Eighth edition, Vol.3, CH 50, p1225, 2008.

150- Jaffe AS, Apple FS: Biomarkers in acute cardiac disease: the present and the future. *Am J Cardiol* 48:1, 2006.

151- Albert JS: Definition of myocardial infarction-a global consensus document of the joint ESC/ACC/AHA/WHF/WHO Task Force, 2007 (in press).

152- Wu AHB: Analytic issues for the clinical use of cardiac troponin. Cardiovascular biomarkers: Pathophysiology and disease management. In Morrow DA (ed): Totowa, NJ, Humana Press, pp 16-40, 2006.

153- Elliott M, Eugene Braunwald: ST-elevation myocardial infarction: Pathology, Pathophysiology and clinical features, *Braunwald's Heart Disease. A Textbook Of Cardiovascular Medicine*: Peter Libby (eds.), Eighth edition, Vol.3, CH 50, p1227, 2008.

154- Marchall T: Evaluating national guidelines for prevention of cardiovascular disease in primary care. *J Eval Clin Pract* 11:452, 2005.

155- Moon JC, De Arenaza DP, Feng YJ, et al: The pathologic bases of Q-wave and non Q-wave myocardial infarction: Cardiovascular magnetic resonance study. *Am J Cardiol* 44:554, 2004.

156- Kleiman N, Lakkis N, Roe MT, et al: Prospective analysis of creatin kinase-MB and comparison with troponin T to predict cardiac risk and benefit of an invasive strategy in patients with non ST-elevation acute coronary syndrome. *Am J Cardiol* 40:1044-1050, 2002.

157- Morrow DA, Cannon CP, Rifai N, et al: Ability of minor elevations of troponin I, T to predict benefit from an early invasive strategy in patients with unstable angina and non ST-elevation myocardial

infarction: Results from a randomized trial. JAMA 286:2405-2412, 2001.

158- Antman EM: Decision making with cardiac troponin tests. N Engl J Med 346:2079, 2002.

159- Gaffe AS, Ven Eyk JE: Degradation of cardiac troponins: Implications for clinical practice. Cardiovascular biomarkers: pathophysiology and disease management. In Morrow DA (ed.): Totowa, NJ, Humana Press, pp 161-174, 2006.

160- Ikeda J, Zenimoto M, Kita M, et al: Usefulness of cardiac troponin I in patients with acute myocardial infarction. Rinsho Byori 50: 982-986, 2002.

161- Nageh T, Sherwood RA, Wallentin L, et al: Cardiac troponin T and I and creatine kinase-MB as markers of myocardial injury and predictors of outcome following percutaneous coronary intervention. Int J Cardiol 92: 285-293, 2003.

162- Pantighini M: Biochemical markers in acute coronary syndromes. LabMedica International 20(6):6-7, 2003.

163- Sciries BM, Morrow DA.: Troponins in acute coronary syndromes. Prog Cardiovasc Dis 47:177-188, 2004.

164- Modified from Antman EM, Anbe DT, et al: ACS/AHA guidelines for the management of patients with MI. American College of Cardiology web site, 2006.

165- Berton G, Cordiano R, Palmieri R, et al : C-reactive protein in acute myocardial infarction : Associations with heart failure. Am Heart J 145:1094, 2003.

166- Ziakas A, Gavriliadis S, Giannoglous G, et al : In-hospital and long-term prognostic value of fibrinogen, CRP and IL-6 levels in pa-

tients with acute myocardial infarction treated with thrombolysis. *Angiology* 57:283, 2006.

167- Rabbini L. Acute coronary syndromes: beyond myocyte necrosis. *N Engl J Med*;345:1057-1058, 2001.

168- Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. *N Engl J Med*;345:1014-1021, 2001.

169- Vorchheimer DA, Fuster V. Inflammatory markers in coronary artery disease: let prevention douse the flames. *JAMA*;286:2154-2155, 2001.

170- Lindmark E, Diderholm E, Wallentin L, Siegbahn A. Relationship between interleukin-6 and mortality in patients with unstable coronary artery disease. *JAMA*;286:2107-2113, 2001.

171- Laurie G, Lemberg L: Novel markers of acute coronary syndrome: BNP, IL-6, PAPP-A. *American journal of critical care*; 11(2):168-171, 2002

172- Azzazy HME, Christenson RH. Cardiac markers of acute coronary syndromes: is there a case for point-of-care testing? *Clin Biochem*; 35: 13±27, 2002.

173- Brennan ML, Penn MS, Van Lente F, et al. Prognostic value of myeloperoxidase in patients with chest pain. *N Engl J Med*; 349: 1595±1604, 2003.

174- Vaananen HK, Syrjala H, Rahkila P et al. Serum carbonic anhydrase III and myoglobin concentration in acute myocardial infarction. *Clin Chem* 36: 635-638, 1990.

175- Beuerle JR, Azzazy HM, Sanhi WR, et al: Characteristics of myoglobin, Carbonic anhydrase III and the myoglobin/ Carbonic anhydrase III ratio in trauma, exercise and myocardial infarction patients. *Clin Chim Acta* 294:115-128, 2000.

176- Vuotikka P, Uusimaa P, Cook EF, et al: Serum myoglobin/ Carbonic anhydrase III ration as a marker of reperfusion after myocardial infarction. *Int J Cardiol* 91:137-144, 2003.

177- Bhagavan NV, Lai EM, Rios PA, et al. Evaluation of human serum albumin cobalt binding assay for the assessment of myocardial ischaemia and myocardial infarction. *Clin Chem*; 49: 581±5, 2003.

178- Peacock F, Morris DL, Anwaruddin S, et al : Meta-analysis of ischemic modified albumin to rule out acute coronary syndrome in emergency department. *Am Heart J* 152:253-262, 2006.

179- Bayes-Genis A, Conover CA, Overgaard MT, et al. Pregnancy-associated plasma protein A as a marker of acute coronary syndromes. *N Engl J Med*;345:1022-1029, 2001.

180- Morrow DA, Cannon CP, Jesse RL, et al : National Academy of Clinical Biochemistry Laboratory medicine practice guidelines : Clinical characteristics and utilization of biochemical markers in acute coronary syndrome. *Circulation* (in press), 2001.

181- Christopher P, Thomas H: Approach to the patient with chest pain, *Braunwald's Heart Disease. A Textbook Of Cardiovascular Medicine*: Peter Libby (eds.), Eighth edition, Vol.3, CH 49, p1200, 2008.

182- Roe MT, Peterson ED, Pollack CV, et al : Influence of timing of troponin elevation on clinical outcomes and use of evidence-based therapies for patients with non ST-segment elevation acute coronary syndrome. *Ann Emerg Med* 45:355-362, 2005.

183- Newby LK, Roe MT, Murphy S, et al: Frequency and clinical implications of discordant creatin kinase-MB and troponin measurements in acute coronary syndromes. *Am J Cardiol* 47:312-318, 2006.

- 184- Kleiman N, Lakkis N, Cannon C, et al: Prospective analysis of creatin kinase-MB and comparison with troponin T to predict cardiac risk and benefit of an invasive strategy in patients with non ST-elevation acute coronary syndrome. *Am J Cardiol* 40:1044-1050, 2002.
- 185- Antman EM, Tanasijevic MJ, Thompson B, et al: Cardiac specific troponin I levels to predict the risk of mortality in patients with acute coronary syndrome. *N Engl J Med* 335:1342-1349, 1996.
- 186- James SK, Barnathan E, Armstrong P, et al: troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome. GUSTO/IV sub-study. *Am J Cardiol* 41:916-924, 2003.
- 187- Kastrati A, Neumann FJ, Mehilli J, et al: Abciximab in patients with acute coronary syndrome undergo percutaneous coronary intervention after clopidogrel pre-treatment : The ISAR/REACT 2 randomized trial. *JAMA* 295:1531-1538, 2006.
- 188- Olatidoye AG, Wu AH, OrganL, et al: Prognostic role of troponin T versus troponin I in unstable angina for cardiac events with meta-analysis comparing published studies. *Am J Cardiol* 81:1405-1410, 1998.
- 189- Preeti Kishore, THE MERCK MANUALS online medical library, retrieved June 2008.
- 190- Patric K, Isley W: Diabetes Mellitus. emedicine Online medical library, retrieved august 2008.
- 191- Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care*;20:1183-97, 1997.
- 192- William H, Arlan L: e-medicine the continually updated clinical reference retrieved Oct 2007.

- 193- Report of the expert committee on diagnosis and classification of diabetes mellitus, from American Diabetes Association. *Diabetes Care*; 26: S5-S20, 2003.
- 194- John A: Oral glucose tolerance tests and long term glucose level: American Diabetes Association; *Diabetes Care*; 32:65, 2007.
- 195- Lusher TF, Creager MA, Beckman JA, et al: Diabetes and vascular disease: Pathophysiology, Clinical consequences and Medical therapy: Part II. *Circulation* 108:1655, 2003.
- 196- Beckman JA, Libby P, Creager MA, et al: Diabetes and atherosclerosis: Epidemiology, Pathophysiology, and Management. *JAMA* 287:2570, 2002.
- 197- Gu K, Harris MI, Cowie CC, et al: Diabetes and decline in heart disease mortality in US adults. *JAMA* 281:1291, 1999.
- 198- Shindler DM, Palmeri ST, Antonell TA, et al: Diabetes mellitus in cardiogenic shock complicating acute myocardial infarction: A report from the SHOCK trial registry. Should we emergently revascularized occluded coronaries for cardiogenic shock? *Am J Cardiol* 63 (Suppl A): 109, 2000.
- 199- Backman JA, Goldfine AB, Gordon NB, et al: Oral anti-oxidant therapy improves endothelial function in type 1 but not type 2 diabetes mellitus. *Am J Physiol Heart Circ Physiol* 285:H2392, 2003.
- 200- Creager MA, Lusher TF, Cosentino F, et al: Diabetes and vascular disease: Pathophysiology, Clinical consequences, and Medical therapy. Part I *Circulation* 108:1527, 2003.
- 201- Goldfine AB, Beckman JA, Betensky RA, et al: Family history of diabetes is a major determinant of endothelial function *Am J Cardiol* 47:2465, 2006.

- 202-Malemborg K, Ryden L, Efendic S, et. al: Randomized trial of insulin-glucose infusion followed by subcutaneous insulin injection in diabetic patients with acute myocardial infarction (DIGAMI) study: Effects of mortality at one year. *Am J Cardiol* 26:57, 1995.
- 203- Malemborg K, Norhammar A, Wedel H, et. al: Glycometabolic state at admission: Important risk marker of mortality in conventionally treated patient with diabetes and acute myocardial infarction: Long-term results from Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study. *Circulation* 99:2626,1999.
- 204- Fath-Ordoubade F, Beatt TJ: Glucose-Insulin-Potassium therapy for treatment of acute myocardial infarction: An overview of randomized placebo-controlled trials. *Circulation* 96:1152, 1997.
- 205- Apstein CS: The benefits of glucose-Insulin-Potassium for acute myocardial infarction. *Am J Cardiol* 42:792, 2003.
- 206- Wang P, Lloyd SG, Chatham JC: Impact of high glucose/high insulin and dichloroacetate treatment on carbohydrate oxidation and functional recovery after low-flow ischemia and reperfusion in the isolated perfused rat heart. *Circulation* 111:2066, 2005.
- 207- Chaudhuri A, Janicke D, Wilson MF, et al: Anti-inflammatory and fibrinolytic effect of insulin in acute ST-segment elevation myocardial infarction. *Circulation* 109:849, 2004.
- 208- Dandona P, Mohanty P, Chaudhuri A, et al: Insulin infusion in acute illness. *J Clin Invest* 115:2069, 2005.
- 209- Sack MN, Yellon DM: Insulin infusion as an adjunct to reperfusion after acute coronary ischemia. A proposed direct myocardial cell survival effect in dependent of metabolic modulation. *Am J Cardiol* 41: 1404, 2003.

- 210- Grover GJ, Gerliod KD: ATP-sensitive potassium channels: A review of their cardio-protective pharmacology. *J Mol Cardiol* 32:677, 2000.
- 211- Richard W. Nesto: Daibetes and heart disease, *Braunwald's Heart Disease. A Textbook Of Cardiovascular Medicine*: Peter Libby (eds.), Eighth edition, Vol.3, CH 60, p1557, 2008.
- 212- UK Prospective Diabetes Study (UKPDS) group: Intensive blood-glucose control with sulfonylurea or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS-33). *Lancet* 352:837, 1998.
- 213- Kahn SE, Hafnr SM, Heise MA, et al: Glycemic durability after rosiglitazone, Metformin, or Glyburid monotherapy. *N Engl J Med* 355:2427, 2006.
- 214- Ghosh S, Standan NB, Galinianes M, et al: Failure of precondition pathological human myocardium. *Am J Cardiol* 37:711, 2001.
- 215- Ishihara M, Inoue I, Kawagoe T, et al: Diabetes mellitus prevents ischemic preconditioning in patients with a first acute anterior wall myocardial infarction. *Am J Cardiol* 38:1007, 2001.
- 216- Quast U, Stephen D, Russ U, et al: The impact of ATP-sensitive potassium channel subtype selectivity of insulin secretagogues for the coronary vasculature and myocardium. *Diabetes* 53(Suppl 3): S 156, 2004.
- 217- Goldstein BJ: Differentiating members of thiazolidinedione class: A focus on efficacy. *Diabetes Metab Res Rev* 18 (Suppl 2): S 16, 2002.
- 218- Nesto RW, Bell D, Bonow RO, et al: Thiazolidinedione use, fluid retention, and congestive heart failure: A consensus statement from the American Heart Association and American Diabetes Association. *Circulation* 108:2941, 2003.

219- Dormandy JA, Charbonnel B, Eckland DJA, et al: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitazone Clinical Trial in macroVascular Events): A randomized controlled trial. *Lancet* 366:1279, 2005.

220- Gerstein HC, Yusuf S, Bosch J, et al: Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomized controlled trial. *Lancet* 368:1096, 2006.

221- Libby P: Metformin and vascular protection: A cardiologist's view. *Diabetes Metab* 29:6S117, 2003.

222- Jonson JA, Majumdar SR, Simpson SH, et al: Decreased mortality associated with the use of Metformin compared with sulfonyl urea monotherapy in type 2 diabetes. *Diabetes care* 25:2244, 2002.

223- Eurich DT, Majumdar SR, McAlister FA, et. al: Improved clinical outcomes associated with metformine in patients with diabetes and heart failure, *Diabetes Care* 28:2345 , 2005.

224- Krenz AJ, Bailey CJ: Oral anti-diabetic agents: Current role in type 2 diabetes mellitus. *Drugs* 65:385, 2005.

225- Christopher P and Eugene Braunwald: Unstable Angina and Non-ST elevation myocardial infarction, *Braunwald's Heart Disease. A Textbook Of Cardiovascular Medicine*: Peter Libby (eds.) , Eighth edition , Vol.3, CH 53 , p1319 , 2008.

226- Ang C. H., Castle S.F, Balaz SN, et. al: Six month follow up of patients who have had cardiac troponin I elevation during routine PCI.browse 48th asm abstracts, 2000.

227- Morrow DA, Cannon CP, Rifai N, et. al: National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines:

Clinical characteristics and utilization of biochemical markers in acute coronary syndrome. *Circulation* 115: e356, 2007.

228- Peduzzi P, Concato J, Kemper E, et al: A simulation study of the number of events per variable in logistic regression analysis. *J Clin Epidemiol.* 49(12):1373-1379, 1996.

229- Labarthe DR. *Epidemiology and Prevention of Cardiovascular Diseases: A Global Challenge*. Gaithersburg, Md: Aspen Publishers; 1998.

230- Chambless L, Keil U, Dobson A, et al. Population versus clinical view of case fatality from acute coronary heart disease: results from the WHO MONICA Project 1985-1990: Multinational Monitoring of Trends and Determinants in Cardiovascular Disease. *Circulation*;96:3849-3859, 1997.

231- Yudkin JS, Oswald GA.: Determinants of hospital admission and case fatality in diabetic-patients with myocardial-infarction. *Diabetes Care*11:351–8, 2000.

232- Kouvaras G, Cokkinos D, Spyropoulou M.: Increased mortality of diabetics after acute myocardial-infarction attributed to diffusely impaired left ventricular performance as assessed by echocardiography. *Jpn Heart J* 29:1–9, 2000.

233- Haffner SM, Lehto S, Ronnema T, et al: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. *N Engl J Med.* 339:229-234, 2001.

234- Alvaro M, Charles H, Gervasio A, et al.: Impact of diabetes on mortality in patients with myocardial infarction and left ventricular dysfunction. *Arch Intern Med.* 164: 2273-2279, 2004.

- 235- Chyun D, Vaccarino V, Murillo J, et.al: Cardiac outcomes after myocardial infarction in patients with diabetes mellitus. *American journal of critical care*; 11:504-519, 2002.
- 236- Norhammar A, Malmberg K, Diderhlom E, et. al: Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of CAD and benefits of revascularization. *J Am Coll Cardiol* 43: 585-591, 2004.
- 237- Kristen Franklin, Robert J, Fredrick Spenser et. al: Implications of diabetes in patients with acute coronary syndrome. *Arch Intern Med*. 164:1457-1463, 2004.
- 238- Malemberg K, Yusuf S, Hertzel C, et.al: Impact of diabetes mellitus on long term prognosis in patients with acute coronary syndrome. Result of Organization to Assess Strategies for Ischemic Syndromes (OASIS) study. *Circulation* 102:1014-1019, 2002
- 239- Sean M, Garrick C, Carolyn H, et al: Diabetes and mortality following acute coronary syndromes. *JAMA*; 298: 765-775, 2007.
- 240- James S, Lindahl J, Timmer J, et. al,: Usefulness of biomarkers for predicting long-term mortality in patients with DM and non ST-elevation ACS (GUSTO IV substudy); 97: 167-172, 2003.
- 241- Antman E, Milenko J, Tanasijevic M, et.al: Cardiac specific troponin I to predict risk of mortality in patients with acute coronary syndrome. *N Engl J Med*; 335: 1342-9.1996
- 242- Ergin A, Ekecik A, Tasdemir K,et.al: Troponin I and CK-MB in the evaluation of prognosis in patients with acute coronary syndrome.Tr *J of medical sciene* 29: 441-445, 1999.
- 243- Spertus A, Rumsfield S, Kimberly J, et.al: One year health status outcome of unstable angina versus myocardial infarction: A prospective, observational cohort study of acute coronary syndrome survivors. *BMC cardiovascular disorders* 7:28, 2007.

244- Lina J, Daiva R: Short-term and one year prognosis of diabetic patients with myocardial infarction. *Medicina* ; 43(7) : 555-561,2007

245- Janion M, Kurzawski J: Difference of clinical course and prognosis of diabetics with myocardial infarction. *Pol Arch Med Wewn* 105(1) 51-8, 2001.

246- Fazel R, Fang J, Kline-Rogers E, et. al: Prognostic value of elevated biomarkers in diabetic and non-diabetic patients admitted for acute coronary syndromes. *BMJ* ;91: 388-390, 2005.